---
title: "AVITA Medical, Inc. (RCEL.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RCEL.US.md"
symbol: "RCEL.US"
name: "AVITA Medical, Inc."
industry: "Biotechnology"
datetime: "2026-04-14T08:26:12.372Z"
locales:
  - [en](https://longbridge.com/en/quote/RCEL.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RCEL.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RCEL.US.md)
---

# AVITA Medical, Inc. (RCEL.US)

## Company Overview

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [avitamedical.com](https://avitamedical.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-14T04:30:16.000Z

**Overall: C (0.44)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 164 / 393 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 11.45% |  |
| Net Profit YoY | 21.44% |  |
| P/B Ratio | -8.99 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 149721175.01 |  |
| Revenue | 71610000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 799.72% | A |
| Profit Margin | -67.85% | E |
| Gross Margin | 82.13% | A |
| Revenue YoY | 11.45% | B |
| Net Profit YoY | 21.44% | B |
| Total Assets YoY | -29.25% | E |
| Net Assets YoY | -470.08% | E |
| Cash Flow Margin | 64.20% | C |
| OCF YoY | 11.45% | B |
| Turnover | 1.05 | A |
| Gearing Ratio | 129.53% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - AVITA Medical, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "11.45%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "21.44%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-8.99",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "149721175.01",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "71610000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "799.72%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-67.85%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "82.13%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "11.45%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "21.44%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-29.25%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-470.08%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "64.20%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "11.45%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "1.05",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "129.53%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -3.08 | 304/393 | - | - | - |
| PB | -8.99 | 529/393 | 58.11 | 54.88 | 54.11 |
| PS (TTM) | 2.09 | 55/393 | 2.23 | 1.91 | 1.58 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | MiMedx (MDXG.US) | A | B | A | B | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | B | B | A |
| 04 | Vertex Pharma (VRTX.US) | A | B | C | B | C | B |
| 05 | Regeneron Pharma (REGN.US) | A | C | C | B | C | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-09T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 3 | 75% |
| Hold | 1 | 25% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.91 |
| Highest Target | 10.07 |
| Lowest Target | 5.39 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/RCEL.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/RCEL.US/norm.md)
- [Related News](https://longbridge.com/en/quote/RCEL.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/RCEL.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**